Keeping Track: US FDA Clears Another CAR-T And Another Novel ADHD Drug; Submissions Blossom
The latest news and highlights from the Pink Sheet’s US FDA Performance Tracker.
You may also be interested in...
The European Medicines Agency has added 13 new drugs to its list of products that are under review for potential pan-EU marketing approval.
Idecabtagene vicleucel for fifth-line multiple myeloma lags GSK’s BCMA-targeting ADC Blenrep, but it is months ahead of J&J/Legend’s CAR-T. Abecma is BMS’s second CAR-T approval this year.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.